ROME Therapeutics Funding & Investors
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
rometx.comTotal Amount Raised: $199,000,000
ROME Therapeutics Funding Rounds
Series B
$72,000,000
Series B Investors
Alexandria Venture InvestmentsSigmas GroupJohnson & Johnson Innovation – JJDCArchVenturesBristol-Myers SquibbAndreessen HorowitzAxon VenturesMirae Asset CapitalSanofi VenturesSection 32Casdin CapitalMass General Brigham VenturesLuma GroupGVRS ParticipatiesCurie.BioSeries B
$77,000,000
Series B Investors
Section 32Sanofi VenturesAlexandria Venture InvestmentsGVArch Venture PartnersCasdin CapitalAndreessen HorowitzMass General Brigham VenturesSeries A
$50,000,000
Series A Investors
GVPartners Innovation FundArch Venture Partners
Funding info provided by Diffbot.